Substandard and falsified medicines (SFMs) pose a great risk to public health worldwide in low and middle-income countries. Vulnerable groups like children are disproportionately exposed. The dangerous medicines vary from useless to poisonous treatment, increase resistant microorganisms, and enhance the disease burden. SFM has led to numerous tragic events in developing countries, which is a major crime against humanity and depicts one of the most intricate safety issues in healthcare systems. This narrative review presents data from available published literature of varying scientific databases, regulatory requirements, and grey literature to compile in-depth information and concentrate on implementing strategies and initiatives for the prevention of SFM among children. The article emphasizes substandard and counterfeit antimalarial’s global effects, poor access to essential quality medicine with probable effects of substandard antibiotics, and effects of substandard analgesics and antipyretic syrup. The strategies include healthcare leadership consolidating the pharmaceutical supply chain with high-end technology, cost-effective analysis, pharmaceutical education, training and awareness, global funds, and other policies. Different organizations’ initiatives at the global level are the International Medical Products Anti-Counterfeiting Taskforce of the World Health Organization and the United Nations International Children’s Emergency Fund, both of which enhance coordination between governments, healthcare professionals, and regulatory authorities. But a multifaceted approach involving greater regulatory and enforcement efforts as well as improved healthcare access, education, and cooperation at the international level is needed to protect children.
Dewan S, Muragundi PM, Ramesh VL, Ligade VS, Sreedhar D, Shetty AD. Substandard and falsified pediatric medicines in low–middle-income countries: A narrative review on impacts and strategies J Appl Pharm Sci. 2025. Article in Press. http://doi.org/10.7324/JAPS.2025.246088
1. Sorato MM, Davari M, Kebriaeezadeh A. Improving access to medicines to reduce marketing and use of substandard and falsified medicines in Africa: scoping review. J Med Access. 2024;8:27550834241236598. https://doi.org/10.1177/27550834241236598
2. Hamilton WL, Doyle C, Halliwell-Ewen M, Lambert G. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies. Health Policy Plan. 2016;31(10):1448-66. https://doi.org/10.1093/heapol/czw062
3. Salami RK, Valente De Almeida S, Gheorghe A, Njenga S, Silva W, Hauck K. Health, economic, and social impacts of substandard and falsified medicines in low- and middle-income countries: a systematic review of methodological approaches. Am J Trop Med Hyg. 2023;109(2):228-40. https://doi.org/10.4269/ajtmh.22-0525
4. Yakhkind A, Lang AE, Brophy G, Tesoro E, Levasseur-Franklin KE, Maldonado N. Substandard and falsified medications: a barrier to global health equity exemplified in ecuador. Neurocrit Care. 2023;38(1):1-6. https://doi.org/10.1007/s12028-022-01658-1
5. Tefera G, Bekele A, Getahun H, Tefera Y. Impact of substandard and falsified medicines on public health: a review. Acta Sci Pharm Sci. 2022;6(6):4-10.
6. Taylor D. RFID in the pharmaceutical industry: addressing counterfeits with technology. J Med Syst. 2014;38(11):141. https://doi.org/10.1007/s10916-014-0141-y
7. McManus D, Naughton BD. A systematic review of substandard, falsified, unlicensed and unregistered medicine sampling studies: a focus on context, prevalence, and quality. BMJ Glob Health. 2020;5(8):e002393. https://doi.org/10.1136/bmjgh-2020-002393
8. Renschler JP, Walters KM, Newton PN, Laxminarayan R. Estimated under-five deaths associated with poor-quality antimalarials in Sub- Saharan Africa. Am J Trop Med Hyg. 2015;92(6_Suppl):119-26. https://doi.org/10.4269/ajtmh.14-0725
9. Bassat Q, Tanner M, Guerin P, Stricker K, Hamed K. Combating poor-quality antimalarial medicines: a call to action. Malar J. 2016;15:302. https://doi.org/10.1186/s12936-016-1357-8
10. The convention on the rights of the child: the children’s version UNICEF [Internet]. [cited 2024 Nov 22]. Available from: https://www.unicef.org/child-rights-convention/convention-text-childrens-version
11. Children United Nations [Internet]. [cited 2024 Nov 20]. Available from: https://www.un.org/en/global-issues/children
12. Tegegne AA, Feissa AB, Godena GH, Tefera Y, Hassen HK, Ozalp Y, et al. Substandard and falsified antimicrobials in selected east African countries: a systematic review. PLoS One. 2024;19(1):e0295956. https://doi.org/10.1371/journal.pone.0295956
13. Higgins CR, Kobia B, Ozawa S. Comparing the return on investment of technologies to detect substandard and falsified amoxicillin: a Kenya case study. PLoS One. 2023;18(1):e0268661. https://doi.org/10.1371/journal.pone.0268661
14. Yahoo News. Indonesia bans cough syrups after nearly 200 child deaths [Internet]. 2022 [cited 2024 Nov 4]. Available from: https://www.yahoo.com/news/indonesia-bans-cough-syrups-nearly-174411645.html
15. Full List of WHO Medical Product Alerts [Internet]. [cited 2024 Jun 29]. Available from: https://www.who.int/teams/regulation-prequalification/incidents-and-SF/full-list-of-who-medical-product-alerts
16. Barr RD, Furneaux R, Margottini L, Eden TOB. The international scandal of defective asparaginase: a blight on children with cancer. Pediatr Blood Cancer. 2023;70(8):e30403. https://doi.org/10.1002/pbc.30403
17. Gray NJ, Barr RD, Karekezi C, Chanoine JP. Substandard and falsified medicines for children: UHC has a preventive role. Lancet Child Adolesc Health. 2023;7(12):821-3. https://doi.org/10.1016/S2352-4642(23)00227-4
18. Rutta E, Liana J, Embrey M, Johnson K, Kimatta S, Valimba R, et al. Accrediting retail drug shops to strengthen Tanzania’s public health system: an ADDO case study. J Pharm Policy Pract. 2015;8(1):23. https://doi.org/10.1186/s40545-015-0044-4
19. Roncone A, Kelly S, Giannioti Z, Hauk C, Caillet C, Newton P, et al. Stable isotope ratio analysis: an emerging tool to trace the origin of falsified medicines. TrAC-Trends Anal Chem. 2024;174:117666. https://doi.org/10.1016/j.trac.2024.117666
20. UNODC World Drug Report 2024: Harms of world drug problem continue to mount amid expansions in drug use and markets United Nations in North Macedonia [Internet]. [cited 2024 Jun 29]. Available from: https://northmacedonia.un.org/en/272585-unodc-world-drug-report-2024-harms-world-drug-problem-continue-mount-amid-expansions-drug
21. Newton PN, Caillet C, Guerin PJ. A link between poor quality antimalarials and malaria drug resistance?. Expert Rev Anti Infect Ther. 2016;14(6):531-3. https://doi.org/10.1080/14787210.2016.1187560
22. Kusynová Z, Bais Y, Van Den Ham HA, Mantel-Teeuwisse AK, Etame-Loe G, Kaale E, et al. Improved knowledge of substandard and falsified (SF) medical products through a dedicated course for pharmacy students at three universities in sub-Saharan Africa. BMJ Glob Health. 2023;6(Suppl 3):e009367. https://doi.org/10.1136/bmjgh-2022-009367
23. Adhikari B, Bayo M, Peto TJ, Callery JJ, Tripura R, Dysoley L, et al. Comparing the roles of community health workers for malaria control and elimination in Cambodia and Tanzania. BMJ Glob Health. 2023;8(12):e013593. https://doi.org/10.1136/bmjgh-2023-013593
24. World Health Organization. Full list of WHO medical product alerts [Internet]. Geneva, Switzerland: WHO; [cited 2024 Jul 29]. Available from: https://www.who.int/teams/regulation-prequalification/incidents-and-sf/full-list-of-who-medical-product-alerts
25. Lima MBA, Yonamine M. Counterfeit medicines: relevance, consequences, and strategies to combat the global crisis. Braz J Pharm Sci. 2023;59:e20402. https://doi.org/10.1590/s2175-97902023e20402
26. Walker EJ, Peterson GM, Grech J, Paragalli E, Thomas J. Are we doing enough to prevent poor-quality antimalarial medicines in the developing world? BMC Public Health. 2018;18(1):630. https://doi.org/10.1186/s12889-018-5521-7
27. Evans DR, Higgins CR, Laing SK, Awor P, Ozawa S. Poor-quality antimalarials further health inequities in Uganda. Health Policy Plan. 2019;34(Supplement_3):iii36-47. https://doi.org/10.1093/heapol/czz012
28. Irungu BN, Koech LC, Ondicho JM, Keter LK. Quality assessment of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya. PLoS One. 2021;16(9):e0257625.https://doi.org/10.1371/journal.pone.0257625
29. Zabala G, Bellingham K, Vidhamaly V, Boupha P, Boutsamay K, Newton P, et al. Substandard and falsified antibiotics: neglected drivers of antimicrobial resistance? BMJ Glob Health. 2022;7(8):e008587. https://doi.org/10.1136/bmjgh-2022-008587
30. Koech LC, Irungu BN, Ng’ang’a MM, Ondicho JM, Keter LK. Quality and brands of amoxicillin formulations in Nairobi, Kenya. BioMed Res Int. 2020;2020(1):7091278. https://doi.org/10.1155/2020/7091278
31. Kelesidis T, Falagas ME. Substandard/Counterfeit antimicrobial drugs. Clin Microbiol Rev. 2015;28(2):443-64. https://doi.org/10.1128/CMR.00072-14
32. Assi S. Identification of counterfeit drugs using dual laser handheld Raman. Eur Pharm Rev. 2015;20(5):20-6.
33. Vandy A, Conteh E, Lahai M, Kolipha-Kamara M, Marah M, Marah F, et al. Physicochemical quality assessment of various brands of paracetamol tablets sold in Freetown Municipality. Heliyon. 2024;10(3):e25502. https://doi.org/10.1016/j.heliyon.2024.e25502
34. Silva MKLD, Barreto FC, Sousa GDS, Simões RP, Ahuja G, Dutta S, et al. Development of an electrochemical paper-based device modified with functionalized biochar for the screening of paracetamol in substandard medicines. Molecules. 2024;29(22):5468.https://doi.org/10.3390/molecules29225468
35. Cavany S, Nanyonga S, Hauk C, Lim C, Tarning J, Sartorius B, et al. The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance. Nat Commun. 2023;14(1):6153. https://doi.org/10.1038/s41467-023-41542-w
36. Gabel J, Lächele M, Sander K, Gnegel G, Sunny-Abarikwu N, Ohazulike RE, et al. Quality of essential medicines from different sources in Enugu and Anambra, Nigeria. Am J Trop Med Hyg. 2024;111(1):179-95. https://doi.org/10.4269/ajtmh.23-0837
37. Soleman S, Adnan M, Sudiarto H, Mahathma S, Tazkia A, Firdaus H, et al. Effects of diethylene glycol contamination of pharmaceutical products on unexplained acute kidney injury in children: a systematic review. Clin Exp Pediatr [Internet]. 2024 [cited 2024 Nov 23];67(8):395-402. Available from: http://e-cep.org/journal/view.php?
38. Kumar P, Rastogi S, Saini PK, Sahoo S, Raghuvanshi RS, Jadaun GPS. Minimizing the risk of ethylene glycol and diethylene glycol poisoning in medications: a regulatory and pharmacopoeial response. Regul Toxicol Pharmacol. 2025;155:105741. https://doi.org/10.1016/j.yrtph.2024.105741
39. Aronson JK. When I use a word . . . medicines regulation-diethylene glycol. BMJ. 2024;384:q356. https://doi.org/10.1136/bmj.q356
40. Petersen A, Held N, Heide L, Difäm-EPN Minilab Survey Group. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab. PLoS One. 2017;12(9):e0184165. https://doi.org/10.1371/journal.pone.0184165
41. Riaz MK, Riaz M, Latif A. Medication errors and strategies for their prevention. Pak J Pharma Sci. 2017;30(3):921-8.
42. Latest Alerts. Central drugs standard control organization [Internet]. [cited 2024 Jun 29]. Available from: https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/
43. Public Alert No. 03/2025 - Alert on the Sale of Counterfeit/Falsified Petsow Starnicillin (Ampicillin) 500mg found in Cameroon and Central African Republic - NAFDAC [Internet]. [cited 2025 Mar 5]. Available from: https://nafdac.gov.ng/public-alert-no-03-2025-alert-on-the-sale-of-counterfeit-falsified-petsow-starnicillin-ampicillin- 500mg-found-in-cameroon-and-central-african-republic/
44. Health products policy and standards [Internet]. [cited 2024 Nov 29]. Available from: https://www.who.int/teams/health-product-policy-and-standards/medicines-selection-ip-and-affordability/medicines-policy/rational-use
45. Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, et al. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries. JAMA Netw Open. 2018;1(4):e181662. https://doi.org/10.1001/jamanetworkopen.2018.1662
46. Nayyar GML, Breman JG, Mackey TK, Clark JP. Falsified and substandard drugs: stopping the pandemic. Am J Trop Med Hyg. 2019;100(5):1058-65. https://doi.org/10.4269/ajtmh.18-0981
47. UNICEF Supply Division. Annual report 2022. Available from: https://www.unicef.org/supply/media/13741/file/UNICEF-Supply-Annual-Report-2022.pdf
48. Mackey TK, Nayyar GML. A review of existing and emerging digital technologies to combat the global trade in fake medicines. Expert Opin Drug Saf. 2017;16(5):587-602. https://doi.org/10.1080/14740338.2017.1313227
49. Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet. 2017;389:403-76. https://doi.org/10.1016/S0140-6736(16)31599-9
50. Clark F. Rise in online pharmacies sees counterfeit drugs go global. Lancet. 2015;386 (10001):1327-8. https://doi.org/10.1016/S0140-6736(15)00394-3
51. Adigwe OP, Onavbavba G, Wilson DO. Challenges associated with addressing counterfeit medicines in Nigeria: an exploration of pharmacists’ knowledge, practices, and perceptions. IPRP. 2022;11:177-86. https://doi.org/10.2147/IPRP.S387354
52. Worku MC, Mitku ML, Ayenew W, Limenh LW, Ergena AE, Geremew DT, et al. Assessment of knowledge, attitude, and practice on substandard and counterfeit pharmaceutical products among pharmacy professionals in Gondar City, North-West Ethiopia. Curr Pharm Teach Learn. 2024;16(10):102140. https://doi.org/10.1016/j.cptl.2024.102140
53. Mackey T, Liang B. Improving global health governance to combat counterfeit medicines: a proposal for a UNODC-WHO-Interpol trilateral mechanism. BMC Med. 2013;11:233.https://doi.org/10.1186/1741-7015-11-233
54. Adepoju P. African nations to criminalize falsified medicine trafficking. Lancet. 2020;395(10221):324. https://doi.org/10.1016/S0140-6736(20)30244-0
55. Bolla AS, Patel AR, Priefer R. The silent development of counterfeit medications in developing countries: a systematic review of detection technologies. Int J Pharm [Internet]. 2020;587:119634. Available from: https://www.embase.com/search/results?subaction=view record&id=L2007335737&from=export
56. Attaran A. Stopping murder by medicine: introducing the model law on medicine crime. Am J Trop Med Hyg. 2015;92(6):127-32. https://doi.org/10.4269/ajtmh.15-0154
57. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2005;2(4):302-8.ttps://doi.org/10.1371/journal.pmed.0020100
58. El-Jardali F, Akl EA, Fadlallah R, Oliver S, Saleh N, El-Bawab L, et al. Interventions to combat or prevent drug counterfeiting: a systematic review. BMJ Open. 2015;5(3):e006290.https://doi.org/10.1136/bmjopen-2014-006290
59. Islam I, Islam M. A blockchain based medicine production and distribution framework to prevent medicine counterfeit. J King Saud Univ-Comput Inf Sci. 2024;36(1):101851.https://doi.org/10.1016/j.jksuci.2023.101851
60. Adepoju P. Kenya sounds alarm over counterfeit cancer drugs. Lancet Oncol. 2024;25(7):834. https://doi.org/10.1016/S1470-2045(24)00293-6
61. Glass BD. Counterfeit drugs and medical devices in developing countries. Res Rep Trop Med. 2014;5:11-22. https://doi.org/10.2147/RRTM.S39354
62. Sylim P, Liu F, Marcelo A, Fontelo P. Blockchain technology for detecting falsified and substandard drugs in distribution: pharmaceutical supply chain intervention. JMIR Res Prot [Internet]. 2018;7(9):e10163. https://doi.org/10.2196/10163
63. Torkzadeh L, Tavana M, Maroufi S, Ghasemi P. Blockchain applications in combating counterfeit drugs: a systematic review. Technol Soc. 2022;68:101866.
64. Hajjou M, Krech L, Lane-Barlow C, Roth L, Pribluda VS, Phanouvong S, et al. Monitoring the quality of medicines: results from Africa, Asia, and South America. Am J Trop Med Hyg. 2015;92(6_Suppl):68-74. https://doi.org/10.4269/ajtmh.14-0535
65. Pal T, Mathai T, Mukherji S. Colorimetric chemosensor for rapid detection of fluoroquinolone load in environmental water bodies, urine, and counterfeit drug testing. Biosens Bioelectron X [Internet]. 2023;14:100384. Available from: https://www.scopus.com/inward/record.uri
66. Schwarz SW, Decristoforo C. US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trial and marketing authorizations. EJNMMI Radiopharm Chem [Internet]. 2019;4(1):10. Available from: https://www.embase.com/search/results
67. Jamróz W, Kurek M, ?yszczarz E, Szafraniec J, Jachowicz R. Application of 3D printing technology in pharmaceuticals. Pharm Res. 2022;39(2):289-302.
68. Norman J, Madurawe RD, Moore CMV, Khan MA, Khairuzzaman A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Adv Drug Deliv Rev. 2017;108:39-50.https://doi.org/10.1016/j.addr.2016.03.001
69. Wang Y, Liu X. Safety signals of albumin-bound paclitaxel: data mining of the Food and Drug Administration adverse event reporting system. Indian J Pharmacol. 2023;55(3):167-73.https://doi.org/10.4103/ijp.ijp64022
70. Luangasanatip N, Khonputsa P, Caillet C, Vickers S, Zambrzycki S, Fernández FM, et al. Implementation of field detection devices for antimalarial quality screening in Lao PDR-a cost-effectiveness analysis. PLoS Negl Trop Dis. 2021;15(9):e0009539.https://doi.org/10.1371/journal.pntd.0009539
71. Khuluza F, Kigera S, Jähnke RWO, Heide L. Use of thin-layer chromatography to detect counterfeit sulfadoxine/pyrimethamine tablets with the wrong active ingredient in Malawi. Malar J [Internet]. 2016;15(1):215. Available from: https://www.embase.com/search/results
72. GPHF The GPHF-MinilabTM [Internet]. [cited 2024 Jul 3]. Available from: https://www.gphf.org/en/minilab/
73. Pan H, Ba-Thein W. Diagnostic accuracy of global pharma health fund MinilabTM in assessing pharmacopoeial quality of antimicrobials. Am J Trop Med Hyg. 2018;98(1):344-8.https://doi.org/10.4269/ajtmh.17-0289
74. Visser BJ, Meerveld-Gerrits J, Kroon D, Mougoula J, Vingerling R, Bache E, et al. Assessing the quality of antimalarial drugs from Gabonese pharmacies using the MiniLab®: a field study. Malar J [Internet]. 2015;14(1):273. Available from: https://www.embase.com/search/results?Subaction=viewrecord&id=L605176591&from=export
75. Gnegel G, Häfele-Abah C, Neci R, Heide L. Surveillance for substandard and falsified medicines by local faith-based organizations in 13 low- and middle-income countries using the GPHF Minilab. Sci Rep. 2022;12(1):13095. https://doi.org/10.1038/s41598-022-17123-0
76. Ozawa S, Haynie DG, Bessias S, Laing SK, Ngamasana EL, Yemeke TT, et al. Modeling the economic impact of substandard and falsified antimalarials in the democratic Republic of the Congo. Am J Trop Med Hyg. 2019;100(5):1149-57. https://doi.org/10.4269/ajtmh.18-0334
77. Shahverdi S, Hajimiri M, Pourmalek F, Torkamandi H, Gholami K, Hanafi S, et al. Iranian pharmacists’ knowledge, attitude and practice regarding counterfeit drugs. Iran J Pharm Res. 2012;11(3):963-8.
78. Jack A. Can anyone stop the illegal sale of medicines online? BMJ. 2016;352:i1317. https://doi.org/10.1136/bmj.i1317
79. Adigwe OP. The role of pharmacists in eliminating counterfeit medicines in Nigeria. Front Public Health. 2023;11:1170929. https://doi.org/10.3389/fpubh.2023.1170929
80. Chambliss WG, Carroll WA, Kennedy D, Levine D, Moné MA, Douglas Ried L, et al. Role of the pharmacist in preventing the distribution of counterfeit medications. J Am Pharm Assoc. 2012;52(2):195-9. https://doi.org/10.1331/JAPhA.2012.11085
81. Persson A, Troein M, Lundin S, Midlöv P, Lenander C. Exploring pharmacists’ perspectives about substandard and falsified medical products through interviews. Explor Res Clin Soc Pharm. 2024;13:100421. https://doi.org/10.1016/j.rcsop.2024.100421
82. Mani G, Danasekaran R, Annadurai K. Substandard, spurious, falsely-labelled, falsified and counterfeit (SSFFC) drugs: time to take a bitter pill. J Krishna Inst Med Sci Univ. 2016;5(4):122-24.
83. CDSCO Drug Alert: 48 Medicine Batches Flagged as Not of Standard Quality in August 2024 - The Doctorpreneur Academy [Internet]. [cited 2025 Jun 3]. Available from: https://thedoctorpreneuracademy.com/2024/09/23/cdsco-drug-alert-48-medicine-batches-flagged-as-not-of-standard-quality-in-august-2024/
84. Counterfeit awareness campaign. [cited 2023 Mar 1]. Available from: https://www.Pfizer.com/counterfeiting/counterfeitawareness campaign
85. El-Dahiyat F, Fahelelbom KM, Jairoun AA, Al-Hemyari. Combatting substandard and falsified medicines: public awareness and identification of counterfeit medications. Front Public Health. 2021;9;1-8. https://doi.org/10.3389/fpubh.2021.754279
86. Bashir A, Galal S, Ramadan A, Wahdan A, El-Khordagui L. Community pharmacists’ perceptions, awareness and practices regarding counterfeit medicines: a cross-sectional survey in Alexandria, Egypt. East Mediterr Health J. 20201;26(5):556-64. https://doi.org/10.26719/emhj.19.058
87. Le Doare K, Barker CIS, Irwin A, Sharland M. Improving antibiotic prescribing for children in the resource-poor setting. Br J Clin Pharm. 2015;79(3):446-55. https://doi.org/10.1111/bcp.12320
88. Global Malaria Programme [Internet]. [cited 2024 Dec 21]. Available from: https://www.who.int/teams/global-malaria-programme
89. Tack B, Vita D, Ntangu E, Ngina J, Mukoko P, Lutumba A, et al. Challenges of antibiotic formulations and administration in the treatment of bloodstream infections in children under five admitted to Kisantu Hospital, Democratic Republic of Congo. Am J Trop Med Hyg. 2023;109(6):1245-59. https://doi.org/10.4269/ajtmh.23-0322
90. Fadlallah R, El-Jardali F, Annan F, Azzam H, Akl E. Strategies and systems-level interventions to combat or prevent drug counterfeiting: a systematic review of evidence beyond effectiveness. Pharm Med. 2016;30(5):263-76. https://doi.org/10.1007/s40290-016-0156-4
91. Press Information Bureau. Government of India issues warning on counterfeit drugs [Internet]. 2025 [cited 2025 Jul 3]. Available from: https://www.pib.gov.in/PressReleasePage.aspx?PRID=1966349
Year
Month